Check how courts have cited this case. Use our free citator for the most current treatment.
No. 8627166
United States Court of Appeals for the Ninth Circuit
United States v. Karawi
No. 8627166 · Decided December 19, 2006
No. 8627166·Ninth Circuit · 2006·
FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
December 19, 2006
Citation
No. 8627166
Disposition
See opinion text.
Full Opinion
MEMORANDUM ** Samer Karawi appeals his conviction on three counts of distributing pseudoephedrine, a listed chemical, with knowledge or reasonable cause to believe that it would be used to manufacture a controlled substance, namely, methamphetamine, in violation of 21 U.S.C. § 841 (c)(2) and 18 U.S.C. § 2 . On appeal, Karawi argues that the district court erred in excluding the testimony of his proffered cultural expert and that the mens rea requirement imposed by 21 U.S.C. § 841 (c)(2) violates due process. We affirm Karawi’s conviction. We review a district court’s exclusion of expert testimony for abuse of discretion. Uni ted States v. Bahena-Cardenas, 411 F.3d 1067, 1078 (9th Cir.2005). The district court excluded the proffered testimony of Karawi’s cultural expert, Dr. Jihad Othman, because the name of the witness and the nature of the testimony was disclosed too late and Karawi had not provided sufficient indication of Dr. Othman’s particular expertise and knowledge. The district court did not abuse its discretion. Our decisions in United States v. Kaur, 382 F.3d 1155 (9th Cir.2004) and United States v. Johal, 428 F.3d 823 (9th Cir.2005) foreclose the contention that 21 U.S.C. § 841 (c)(2) imposes a constitutionally insufficient mens rea requirement. Perhaps in recognition of this binding precedent, Karawi argued for the first time in his reply brief that the district court erred in not instructing the jury on the meaning of “reasonable cause to believe.” Because this argument was not raised in his opening brief, Karawi has waived it. Even if it was not waived, we would review only for plain error because Karawi failed to request such an instruction or object to Jury Instruction 20 1 at trial. See, e.g., United States v. Tirouda, 394 F.3d 683, 688 (9th Cir.2005). There was no plain error here. “Whether a term in a jury instruction requires definition normally turns on whether it expresses a concept within the jury’s ordinary experience. No prejudice results from a district court’s failure to define a concept within the comprehension of the average juror.” Id. at 688-89 (citation and internal quotation marks omitted). The phrase “reasonable cause to believe” expresses a concept within the comprehension of the average juror. AFFIRMED. This disposition is not appropriate for publication and may not be cited to or by the courts of this circuit except as provided by 9th Cir. R. 36-3. . Jury Instruction 20 instructed, in relevant part, "defendant distributed pseudoephedrine with knowledge or reasonable cause to believe that it would be used to manufacture methamphetamine.”
Plain English Summary
MEMORANDUM ** Samer Karawi appeals his conviction on three counts of distributing pseudoephedrine, a listed chemical, with knowledge or reasonable cause to believe that it would be used to manufacture a controlled substance, namely, methamp
Key Points
01MEMORANDUM ** Samer Karawi appeals his conviction on three counts of distributing pseudoephedrine, a listed chemical, with knowledge or reasonable cause to believe that it would be used to manufacture a controlled substance, namely, methamp
02On appeal, Karawi argues that the district court erred in excluding the testimony of his proffered cultural expert and that the mens rea requirement imposed by 21 U.S.C.
03We review a district court’s exclusion of expert testimony for abuse of discretion.
04The district court excluded the proffered testimony of Karawi’s cultural expert, Dr.
Frequently Asked Questions
MEMORANDUM ** Samer Karawi appeals his conviction on three counts of distributing pseudoephedrine, a listed chemical, with knowledge or reasonable cause to believe that it would be used to manufacture a controlled substance, namely, methamp
FlawCheck shows no negative treatment for United States v. Karawi in the current circuit citation data.
This case was decided on December 19, 2006.
Use the citation No. 8627166 and verify it against the official reporter before filing.